OS Therapies Incorporated
AMEX:OSTX · New York Stock Exchange American
-$0.01 today
Vol 1.09M · Avg 0.70M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
471.7%
avg -81.7%
ROIC
582.9%
avg 18.9%
ROA
-420.4%
avg -843.8%
Analysis
ROIC is currently the strongest return metric at 582.9% versus its period average of 18.9%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Paul A. Romness | Founder, Chairman, President & Chief Executive Officer | $722,168.00 | — | 59 | $1.00M | 2.25% |
Robert G. Petit | Chief Medical Officer & Chief Scientific Officer | $420,000.00 | — | 66 | $100,000.00 | 0.22% |
Christopher Acevedo | Chief Financial Officer | $36,000.00 | — | 62 | $100,000.00 | 0.22% |
Jack Doll | Chief of Staff | — | — | — | — | — |
Gerald E. Commissiong | Chief Business Officer | — | — | 43 | — | — |
Craig Eagle | Chief Medical Advisor & Member of Strategic Advisory Board | — | — | 59 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Adagene Inc.
NASDAQ:ADAG
$134.41M
Equillium, Inc.
NASDAQ:EQ
$99.82M
Spruce Biosciences, Inc.
NASDAQ:SPRB
$71.19M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$66.38M
MiNK Therapeutics, Inc.
NASDAQ:INKT
$59.88M
Coeptis Therapeutics, Inc.
COEP
$57.63M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$50.19M
CervoMed Inc.
CRVO
$22.68M
Werewolf Therapeutics, Inc.
HOWL
$18.52M
IO Biotech, Inc.
IOBT
$885,690.00
Who manages OSTX?
OS Therapies Incorporated (OSTX) lists 6 active executives. The top listed executive is Christopher Acevedo, Chief Financial Officer.
Are OSTX insiders buying or selling?
Recent insider activity shows net buying of $48.07B.
Explore More
Continue the stock analysis
Jump to another research area for this company.